Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018. Source: BioSpace

The U.S. Food and Drug Administration is set to rule on Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase (SYK) inhibitor, for adult patients with chronic or persistent immune thrombocytopenia…

The Suzhou-based cancer-drug maker has been discussing a valuation of more than $1 billion. Source: BioSpace

Here are three biopharma stocks worth keeping an eye on. Source: BioSpace

The purpose of the subsidiary is to support the Company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s…

Based in Santa Clara, California, CBT Pharma was spun out of Crown Bioscience with four development-stage assets in the oncology space. Source: BioSpace

The EU approval is based on data from three pivotal Phase III studies from the ORCHESTRA trial programme of 2,388 patients who met primary and nearly all key secondary endpoints.…

A look at 6 up and coming blood-testing startups. Source: BioSpace

A federal judge has temporarily blocked the Trump administration's efforts to wind down DACA. Source: BioSpace

Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace